CODEXIS INC (CDXS) Stock Price & Overview

NASDAQ:CDXS • US1920051067

Current stock price

2.61 USD
-0.01 (-0.38%)
Last:

The current stock price of CDXS is 2.61 USD. Today CDXS is down by -0.38%. In the past month the price increased by 63.75%. In the past year, price increased by 15.93%.

CDXS Key Statistics

52-Week Range0.9583 - 3.87
Current CDXS stock price positioned within its 52-week range.
1-Month Range1.43 - 2.75
Current CDXS stock price positioned within its 1-month range.
Market Cap
237.171M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.52
Dividend Yield
N/A

CDXS Stock Performance

Today
-0.38%
1 Week
+13.91%
1 Month
+63.75%
3 Months
+55.95%
Longer-term
6 Months -2.78%
1 Year +15.93%
2 Years -9.97%
3 Years -33.16%
5 Years -88.70%
10 Years -16.83%

CDXS Stock Chart

CODEXIS INC / CDXS Daily stock chart

CDXS Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to CDXS. When comparing the yearly performance of all stocks, CDXS is one of the better performing stocks in the market, outperforming 85.62% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CDXS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CDXS. Both the profitability and financial health of CDXS have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CDXS Earnings

On March 11, 2026 CDXS reported an EPS of 0.11 and a revenue of 38.91M. The company beat EPS expectations (356.77% surprise) and beat revenue expectations (6.47% surprise).

Next Earnings DateMay 12, 2026
Last Earnings DateMar 11, 2026
PeriodQ4 / 2025
EPS Reported$0.11
Revenue Reported38.915M
EPS Surprise 356.77%
Revenue Surprise 6.47%

CDXS Forecast & Estimates

13 analysts have analysed CDXS and the average price target is 6.71 USD. This implies a price increase of 157.28% is expected in the next year compared to the current price of 2.61.

For the next year, analysts expect an EPS growth of 15.26% and a revenue growth 10.49% for CDXS


Analysts
Analysts81.54
Price Target6.71 (157.09%)
EPS Next Y15.26%
Revenue Next Year10.49%

CDXS Groups

Sector & Classification

CDXS Financial Highlights

Over the last trailing twelve months CDXS reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 42.22% compared to the year before.


Income Statements
Revenue(TTM)70.39M
Net Income(TTM)-43.97M
Industry RankSector Rank
PM (TTM) N/A
ROA -29.75%
ROE -87.03%
Debt/Equity 0.79
Chartmill High Growth Momentum
EPS Q2Q%184.62%
Sales Q2Q%81.34%
EPS 1Y (TTM)42.22%
Revenue 1Y (TTM)18.61%

CDXS Ownership

Ownership
Inst Owners72.84%
Shares90.87M
Float83.75M
Ins Owners7.41%
Short Float %8.28%
Short Ratio2.64

About CDXS

Company Profile

CDXS logo image Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 146 full-time employees. The company went IPO on 2010-04-22. The company is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The firm utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. The company is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The firm also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Company Info

IPO: 2010-04-22

CODEXIS INC

200 Penobscot Dr

Redwood City CALIFORNIA 94063 US

CEO: John J. Nicols

Employees: 146

CDXS Company Website

CDXS Investor Relations

Phone: 16504218100

CODEXIS INC / CDXS FAQ

Can you describe the business of CODEXIS INC?

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. The company is headquartered in Redwood City, California and currently employs 146 full-time employees. The company went IPO on 2010-04-22. The company is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The firm utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. The company is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The firm also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.


Can you provide the latest stock price for CODEXIS INC?

The current stock price of CDXS is 2.61 USD. The price decreased by -0.38% in the last trading session.


Does CDXS stock pay dividends?

CDXS does not pay a dividend.


What is the ChartMill rating of CODEXIS INC stock?

CDXS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Can you provide the market cap for CODEXIS INC?

CODEXIS INC (CDXS) has a market capitalization of 237.17M USD. This makes CDXS a Micro Cap stock.


Can you provide the upcoming earnings date for CODEXIS INC?

CODEXIS INC (CDXS) will report earnings on 2026-05-12.